What epitalon is sold on, and what the best evidence for each claim actually is
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
| Claim as marketed | Claim as marketed | Best evidence that exists | Grade | Provenance | Source |
|---|---|---|---|---|---|
| Activates telomerase | Activates the enzyme that rebuilds telomeres | Telomerase induction in telomerase-negative human fetal fibroblast culture (2003), independently reproduced with hTERT and telomerase assays in human cell lines in 2025 | In vitro | Originating group, then independent (Brunel University London) | source |
| Lengthens telomeres in humans | Lengthens your telomeres | Blood lymphocytes from 11 men treated in a dish: telomere length rose in 5 donors and fell in 2, which the authors call a tendency toward normalization. No study has given epitalon to a person and measured telomeres | In vitro | Originating group | source |
| Reduces mortality | Cuts death rates in older people, up to 4-fold | A 266-person clinical assessment over 6 to 8 years and a 15-year follow-up of 79 coronary patients. Both tested Epithalamin, the pineal extract, not epitalon | human-observational | Originating group (developers of both preparations) | source |
| Restores melatonin and sleep | Restores your natural melatonin rhythm | In elderly subjects the extract raised night melatonin only where pineal function was already low and melatonin tended to FALL where function was normal; plus a primate study with no stated animal count | Human trial | Originating group | source |
| Extends lifespan | Extends lifespan | The best-designed mouse study found NO change in mean lifespan; maximum lifespan rose 12.3 percent. Two rat studies found no change under normal lighting. Fruit fly lifespan rose 11 to 16 percent with no dose-response | Animal | Originating group | source |
| Anti-cancer | Protects against cancer | Fewer and smaller tumors across several rodent models, including a mainstream oncology journal. In the same experiments the sibling peptide Vilon significantly increased cancer incidence | Animal | Originating group and collaborations | source |
| No side effects | Has no side effects | Two sentences inside efficacy papers by the originating group. No dedicated safety study, no toxicology study, no adverse-event surveillance and no long-term human data exist | Absence of evidence | Originating group | source |
Every row names the strongest source for the claim, not the weakest, and then states what species it was measured in and who measured it. Where independent replication exists it is credited.